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Human  serum  albumin  (HSA)  is  the most  abundant  protein  in  the  human  body.  HSA  injections  prepared
by  fractionating  human  blood  have  mainly  covered  the  demand  for  albumin  to treat  hypoalbuminemia,
the  state  of  low  concentration  of  albumin  in blood.  HSA  in  solution  may  exist in  various  forms  such
as  monomers,  oligomers,  polymers,  or  as  mixtures,  and  its conformational  change  and/or  aggregation
may  occur  easily.  Considering  these  characteristics,  there  is a great  chance  of  modiﬁcation  and  polymer




binding  (ACB)  test  reported  by Bar-Or  et al. was  originally  designed  to detect  ischemia  modiﬁed  albumin
(IMA),  which  contains  the modiﬁed  HSA  N-terminal  sequence  by cleavage  of the last  two  amino  acids.
In  this  study,  we  developed  a cobalt  albumin  binding  (CAB)  assay  to  correct  the  ﬂaws  of  the  ACB  test
with  improving  the  sensitivity  and  precision.  The  newly  developed  CAB  assay  easily  detects  albumin
conﬁguration  alterations  and  may  be able  to be used  in developing  a quality  control  method  for  albumin
and  its  pharmaceutical  formulations  including  albumin  injections.. Introduction
Human serum albumin (HSA) is the most abundant protein (ca
.7 mM in plasma) in the circulatory system [1]. It is mainly biosyn-
hesized in the liver, regulates colloidal osmotic blood pressure, and
upplies amino acids during malnutrition [2]. HSA is composed of
85 amino acids (66,438 Da), containing 17 pairs of intra-molecular
isulﬁde bridges and one free cysteine (Cys34) [3]. HSA has the
nique capability of binding reversibly or covalently to a wide
iversity of ligands including water, cations (such as Ca2+, Na+, and
+), fatty acids, hormones, bilirubin, and drugs [4,5]. The high bind-
ng afﬁnity of HSA to certain drugs plays an important role in drug
fﬁcacy such as activity, distribution, rate of excretion, and toxic-
ty in the body [3,6]. Inadequately low levels of HSA in the blood,
alled hypoalbuminemia, are common in ill patients regardless of
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their disease types [7]. Hypoalbuminemia is caused by dysfunction
of albumin biosynthesis or albumin loss such as occurs in surgery,
hemorrhagic shock, burn, or nephritic syndrome [8–11]. The treat-
ment for hypoalbuminemia is mainly covered by 5%, 20%, or 25%
albumin injections which are made from albumin isolated by frac-
tionating human blood. Albumin injections are usually sterilized by
heating at 60 ± 0.5 ◦C for 10–11 h in order to inactivate any viruses
that may  contaminate the product during the fractionating pro-
cess. This sterilization progress is likely to induce denatured HSA
[3,4,12,13].
Albumin undergoes conformational transitions as the pH
changes [14], and may  exist as monomeric, oligomeric, and/or poly-
meric forms when in solution [1,15]. Considering the characteristics
of albumin such as its easy aggregation and/or conformational
changes, there is a great chance of albumin modiﬁcation and/or
polymerization during the preparation processes of albumin injec-
tions [16,17]. No severe side effects have been reported so far,
and so the amount of polymers in albumin products is currently
regarded as harmless. The side effects of albumin injections includ-
ing high blood pressure, fever, tachycardia, tremor, ﬂushing, rash
and chills are increasingly being reported [18]. Research is still
ongoing to clarify whether conformational changes of HSA and
the variable portions of aggregations of HSA affect its physiological
roles and/or side effects. Therefore, quantitative analysis of mod-
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ssential process in albumin-related research ﬁelds as well as in
he quality control of the ﬁnal products of albumin.
When myocardial ischemia (MI) occurs, hypoxia followed by
cidosis and destruction of Na+–K+ pump leads to formation of
schemia-modiﬁed albumin (IMA) by cleavage of the ﬁrst two
mino acids (Asp-Ala) of the HSA N-terminus. IMA  is known to have
ow binding afﬁnities toward transition metals including cobalt
Co), copper (Cu), and nickel (Ni), since the ﬁrst 4 residues of the
SA N-terminal, N-Asp-Ala-His-Lys, is recognized as a strong bind-
ng site for those metals [19,20]. IMA  levels increase within a few
inutes of MI  and persist for up to 6–12 h and thus are measur-
ble before myocardial necrosis, making IMA  a relatively efﬁcient
iomarker for early diagnosis of MI  [21–25]. Bar-Or et al. ﬁrst estab-
ished an albumin cobalt binding (ACB) test [26], a method used in
linics to measure IMA  levels in the patient’s blood. The ACB test
as developed at Ischemia Technologies Incorporate (Denver, CO),
nd was approved by the American Food and Drug Administration
FDA) in 2003 as a new method for ruling out myocardial infarction
mong patients coming to the emergency department with chest
ain by measuring the amount of IMA  in the blood. Brieﬂy, as a
uantitative analytical method, the ACB test is performed by the
ddition of a CoCl2 patient plasma sample, followed by the addi-
ion of dithiothreitol (DTT) that binds with the free Co2+ unbound
o serum albumin, and ﬁnally detection for the brown color of the
o-DTT complex [26].
This ACB test reported by the Bar-Or group (to be referred to
s the ACB test) has some limitations; most importantly, many
tudies these days indicate that cobalt binding does not mainly
ccur at the HSA N-terminus [27,28]. Second, the accuracy of test
s not assured due to the lack of available standard HSA because
he majority of HSA on sale exists in denatured forms [29]. Third,
ccording to an investigation on the mode of action of Co-HSA bind-
ng, inconsistent results were shown between the ACB test and
C/MS detection [30]. Fourth, we observed that the results in the
eading scale of absorbance unit (ABSU) by the ACB test did not
ppear sensitive enough to detect the changes in the amount of
lbumin applied to the test. The original test method is used to ana-
yze clinical samples only, which indicates no complement exists
gainst any possible changes in the pH and a relatively large blood
ample volume is needed for each experiment [21]. Accordingly, it
as become necessary to modify the ACB test so that it is capable
f detecting changes in the binding afﬁnities between cobalt and
onformational-modiﬁed albumins with good sensitivity, and able
or reducing the amount of the HSA sample required.
In this study, we modiﬁed and complemented the ACB test and
eveloped a new method (to be called the cobalt albumin binding
CAB) assay), which was optimized to be applicable to not only ana-
yzing clinical samples but also to detecting the different binding
fﬁnities between structurally modiﬁed albumins and cobalt. We
hose a buffer system for the CAB assay, reduced the necessary sam-
le volume, and optimized the reaction ratio of the reagents and
ther factors that may  affect the outcomes of this assay. Through
his simple and down-scaled CAB assay, it will soon be possible to
nalyze structural differences of HSA in various environments with
ase and in a shorter time.
. Experimental and methods
.1. Materials and apparatus
Sodium phosphate monobasic (NaH2PO4), cobalt chloride
CoCl2•6H2O), dithiothreitol (DTT), phosphoric acid (H3PO4),
odium hydroxide (NaOH), lyophilized powder HSA, and urea
ere purchased from Sigma–Aldrich (USA). 20% albumin injection
as obtained from Green Cross Corp. (Korea). All solutions were Biomedical Analysis 91 (2014) 17– 23
prepared using double distilled water. ABSU was detected using
an ELISA Microplate Reader (VersaMax, Molecular Devices). Heat
shock was given with the Dry Block Heating Thermostat (Seoulin,
Korea).
2.2. Development of CAB assay
Using concentrated H3PO4 and NaOH solutions, buffers with dif-
ferent pH conditions ranging from 2.1 to 8 were used to observe
the pH effects on Co2+ and DTT binding, which were measured
by means of an ABSU at 470 nm.  A ﬁnal concentration of 50 mM
NaH2PO4 was chosen as the buffer in the CAB assay, with the pH
set to 7.4 using the NaOH solution. The molar ratio of Co2+ to DTT
was tested in a range of 1–7 in order to ﬁnd the best binding ratio, by
ﬁxing the Co2+ to 0.063 M and increasing the amount of DTT. The
incubation time between Co2+ and HSA was screened from 10 to
60 min  to see how it affected the reaction. After Co2+ and HSA were
mixed, DTT solution was added and the mixture was incubated for
2 min. NaCl solution was added to make a ﬁnal concentration of
0.9%.
To ﬁnd any cobalt-binding competition between HSA and DTT,
the ABSU470 differences according to the addition orders of each
reagent were calculated; ﬁrst, Co2+ and HSA were added followed
by DTT as the ACB test, and second, Co2+ and DTT added followed
by HSA.
2.3. Linearity
In order to validate the linearity of the developed CAB assay, we
prepared 30% HSA with lyophilized powder HSA in double distilled
water, diluted them to 1–25% HSA, and performed a CAB assay with
each albumin concentration. The absorbance value of the blank test
(Co2+ and HSA in reaction buffer without DTT) was subtracted from
the ABSU470 of each sample.
2.4. Precision
20% HSA was used to observe intra- and inter-day precision. The
intra-day precision test was  performed as ﬁve repeated tests on the
same day, and the inter-day precision test was accomplished as the
same tests throughout ﬁve different days. Precision was calculated
to the coefﬁcient of variation (CV, %), which is;
Coefﬁcient of variation (CV%)
= standard deviation of ABSU470
mean of ABSU470
× 100
2.5. Comparison of the CAB assay with the ACB test
The optimized CAB assay method was  compared to that of the
ACB test. The ACB test was  performed exactly as it was  [26], but the
ﬁnal reaction volume was reduced to 200 l as same as that of CAB
assay by reducing the volume size of each of reagents in the same
rate. The ﬁnal concentration was given in parenthesis; 7.7 l of
0.1% CoCl2 (0.1618 mM)  and 30.8 l of the sample were mixed and
incubated for 10 min, and 7.7 l of 1.5 mg/ml  DTT (0.3744 mM)  was
treated followed by addition of 153.8 l of 0.9% NaCl (118.4 mM)
and incubated for 2 min. The two tests were carried out using 20%
HSA with addition of H3PO4 to observe any pH disturbances.
2.6. Detection of diverse conformational changes in HSATo observe any conformational alterations when nitrogen
monoxide (NO) was  added to the HSA, we added NO stock solu-
tion to make 0, 1, 10, 100 and 300 M NO in 20% HSA, and
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Fig. 1. Evaluation of factors that affect the ABSU470 to optimize the CAB assay. (A) Effect of pH on the Co-DTT interaction. Equal amounts of Co2+ and DTT were mixed in































phe  amount of DTT was increased. (C) Effect of different incubation times on Co-HSA
t  was  incubated for various times. Co2+ completed its binding with HSA within 10 m
ifferentiated them by 8% sodium dodecyl sulfate- (SDS-) and
ative-polyacrylamide gel electrophoresis (-PAGE); no reducing
gents were involved in the native gel electrophoresis. The NO stock
olution was prepared by purging NO gas into H2O, which was  sat-
rated to 1.91 mM [31]. Since the NO addition could decrease the
H of the CAB assay reaction buffer, each control sample was set
o the same pH as that of the NO-added sample, using only H3PO4
n order to exclude any pH effects. Also, ovalbumin was tested the
ame way as the HSA to conﬁrm the speciﬁcity toward the human
pecies.
Besides HSA is subject to reversibly change its conformation by
H change [13], adopting the fact that proteins are generally dena-
ured by heat and urea [32,33], heat (79 ◦C for 3 min) and/or 8 M
rea were applied to the 20% HSA, making the 10% HSA in the
nal concentration, with or without 4 M urea. Each sample with
ither heat or urea treatment was compared to each control sam-
le through CAB assay and native gel electrophoresis. Then both
eat and urea were applied to each sample but in a different order,
nd the results were also examined by CAB assay and native gel
lectrophoresis.
.7. Statistical analysis
All experiments were repeated at least three times and the
esults were shown as mean ± standard deviation. Statistics were
alculated using one way analysis of variance (ANOVA) (Graph-
ad Instat, USA) and p < 0.05 between two values was considered
tatistically signiﬁcant.
. Results and discussion
.1. Optimization of conditionsThe decrease of pH affected Co-DTT binding which was not
etectable at low pHs (<6.2), but binding increased with pH increase
Fig. 1A). This result supported that the assay method has to be
H change-resistant. We  chose a ﬁnal concentration of 50 mMng. After adding 20% HSA solution to the reaction buffer containing 0.063 M CoCl2,
NaH2PO4 buffer solution (pH 7.4) as the CAB assay reaction buffer.
The buffering capacity of the reaction buffer protects from leading
to false result, if the remaining Co2+ after Co-HSA binding was not
completely bound to DTT due to pH decrease in the test reaction
solution. The ACB test established by Bar-Or et al., which indirectly
measures IMA  levels [26], was once considered useful in clinics
and performed with only human blood samples. Therefore, the ACB
test was not required to have a buffering capacity [22,23,26]. How-
ever, a few limitations of this test for measuring IMA  to monitor
ischemia have been proposed, as research in this ﬁeld has grown
[27–30]. Especially for albumin-related research such as consid-
ering the amount of endogenous normal conformation-adopted
albumin for monitoring the drug efﬁcacy or metabolism in the
mouse-disease model [6] and proving high quality-controlled albu-
min  inject formulation, it is necessary to have a buffering capacity
and a miniature system available for small sample volumes.
Then we  looked for the absolute amount of DTT that would
be enough to consume all the remaining Co2+ after the Co-HSA
binding. Theoretically, the optimum ratio of Co2+ (possessing 6
coordination sites) to DTT (bidentate ligand) is 1:3. However, DTT
was likely to form a six-membered ring with an internal disulﬁde
bond. This was  clearly identiﬁed by 1H NMR  spectra after the DTT
stock solution was  kept under 2–8 ◦C. Even in the freshly-prepared
DTT solution, the form of a six-membered ring of DTT already co-
existed with the reduced form (Fig. S1 in Supplementary Material).
Therefore, the ratio of Co2+ to DTT was set to 1:4, which was  the
saturation point of the Co-DTT interaction (Fig. 1B). At this point
the remaining free Co2+ after Co-HSA binding was  seemingly fully
detected by DTT. After ﬁxing the Co-DTT ratio, Co2+ and HSA were
then incubated for a range of time from 10 min  to 60 min  as desig-
nated in Fig. 1C. As a result, Co2+ completed its binding with HSA
within 10 min  and the binding remained until 60 min  (Fig. 1C). The
adequate incubation time between Co2+ and HSA was  set to 10 min,
as the ACB test.
Based on the results so far, the new CAB assay was set as fol-
lows to make it possible for high-throughput screening (HTS) in
96-well plates. 0.5% Co2+ stock solution 3 l (0.3152 mM)  and HSA








dated with good linearity and trustworthy reproducibility (Fig. 2)
as the ﬁnal protocol was set after optimization of various conditions
F
b
aig. 2. Linearity of CAB assay. 40 l of each HSA sample solution was  prepared and
nalyzed by the ﬁnalized CAB assay method.
r peptide sample 40 l were added to the buffer solution 131.8 l
50 mM NaH2PO4, pH 7.4 as a ﬁnal concentration), and were incu-
ated for 10 min  at room temperature. 7.5 mg/ml  DTT solution
.2 l (1.2642 mM)  was then added to detect the remaining free
o2+. Then 9% NaCl 20 l (excess salt, 154.0 mM)  was  ﬁnally added
ig. 3. Speciﬁcity of the CAB assay for the human species. (A) ABSU470 changes after addi
oth  SDS- and native-PAGE to verify the conformational changes by the NO treatments. (C
s  (A) and (B). Bars represent mean ± S.D. from three different experiments performed in Biomedical Analysis 91 (2014) 17– 23
to quench the Co-DTT reaction. The ABSU of the ﬁnal mixture in a
total volume of 200 l was measured at 470 nm.
3.2. Validation of the CAB assay
To conﬁrm the linearity of this new method, different con-
centrations ranging from 1 to 25% HSA were tested. In this step,
we proved that Co2+ binding afﬁnity to HSA was  concentration-
dependent, seeing that the ABSU470 decreased depending on
the decrease of the HSA concentration. The result was  reliable
with R2 = 0.9912 (Fig. 2).
Intra- and inter-day precision experiments were also performed
to observe the precision of the CAB assay. The intra-day precision
experiment was performed on the same day with ﬁve replicates
of the same sample. Calculated to the coefﬁcient variation, CV %
was 4.36. The inter-day precision experiment was performed with
the same sample throughout ﬁve different days, and the CV % was
calculated at 3.31. Based on the results, the CAB assay was vali-(Fig. 1). The CAB assay conditions seemed appropriate for steady
maintenance of the Co-HSA interaction and we  found that it was
possible to predict the HSA concentration in a sample use of the CAB
assay.
tion of various concentrations of NO to 20% HSA. (B) Each sample was analyzed by
 and D) Experiments using 20% ovalbumin were performed in the same conditions
 triplicates. *p < 0.05 signiﬁcantly different from the value of the control.































fig. 4. Detection of HSA conformational changes induced by heat and/or urea tre
igniﬁcantly different from the value of control.
.3. Conformational alterations of HSA by NO treatment and
peciﬁcity experiments
Since it has been reported that NO generated a decrease in
inding of the steroid hormones to albumin due to NO-induced
onformational changes in albumin [34], different concentrations
f NO were added to the 20% HSA to observe whether the CAB assay
as able to detect NO-induced changes in albumin. The pH of the
ontrol was adjusted with phosphoric acid to the same pH of the
O-treated albumin sample to avoid false results being produced
y the pH on albumin conformation or Co-DTT binding. As shown
n Fig. 3A, no changes in the binding afﬁnity occurred in the CAB
ssay until 100 M NO was added (with exclusion of the pH effects),
ut a signiﬁcant change was observed when 300 M NO was added
gray bar vs. black bar). The pH effect on Co-DTT complex formation
as also observed in the control by mixing NO with PBS instead
f 20% HSA (Fig. 3A, shaded bar). It was observed that Co-DTT
omplex formation decreased when NO was added, due to the low-
red pH. When 300 M NO was added, there were no differences on
he SDS gel, but as the band was quite different from the others on
he native gel (Fig. 3B, upper panel), it was conﬁrmed that albumin
onformation had been altered by NO treatment. Native gels were
reviously used to observe structural effects [35–37]. The result of
H adjustments showed no differences in both the native and SDS
els (Fig. 3B, lower panel). Therefore, structural modiﬁcation of the
00 M NO-treated albumin was not made by the pH effect, but by
O.
To verify the speciﬁcity of the optimized CAB assay towarduman albumin, the same experiments with ovalbumin were per-
ormed under the same conditions as the NO-treated HSA. The
ative gel results showed that ovalbumin also went through con-
ormational changes when a ﬁnal concentration of 300 M NO wast with native gel electrophoresis (A and C) and CAB assay (B and D). ***p < 0.001,
added (Fig. 3D), but the ABSU470 of the CAB assay did not decrease
when the pH effects were compensated for (Fig. 3C). Therefore,
it can be said that the CAB assay speciﬁcally detects HSA and
its conformational alterations over those of ovalbumin. Protein
nitration induced by nitrogen monoxide (NO) has been broadly rec-
ognized among the various redox posttranslational modiﬁcations
by immunological, spectroscopic, and chromatographic methods
[38,39], reﬂecting that albumin products prepared by human blood
fractionation are likely to have NO-induced structure-modiﬁed
albumin. Fig. 3 shows that 300 M NO treatment induced con-
formational changes, and it was veriﬁed that the developed CAB
assay was  a facile method for detecting altered Co-binding afﬁnity
of NO-induced structurally modiﬁed albumin. Unlike HSA, there
are no known metal binding sites at the N-terminus of ovalbumin
so far. However, it has been previously observed that ovalbumin
interacts with various metal ions including Co2+ [40,41]. Despite
these reports, CAB assay was also capable of distinguishing human
albumin structural modiﬁcations over those of ovalbumin.
3.4. Detection of diverse conformational changes in HSA
We further evaluated whether this new CAB assay could provide
information on albumin conﬁguration alterations induced by other
stimulants besides NO. Albumin samples were treated with heat
and/or urea and then were analyzed through both native gel elec-
trophoresis and CAB assay (Fig. 4). HSA polymerization was  induced
by heat and it was intensiﬁed by co-treatment of both heat and urea
(Fig. 4A, lane 2 vs. 4). HSA polymerization induced by only heat did
not affect much Co-HSA binding (Fig. 4B, bar 1 vs. 2). In contrast,
samples treated with only urea showed no severe polymerization
on the native gel (Fig. 4A, lane 1 vs. 3), but Co-HSA binding was  sig-
niﬁcantly reduced (Fig. 4B, bar 1 vs. 3). When samples were treated
22 E. Lee et al. / Journal of Pharmaceutical and














































[ared with or without addition of 10 mM H3PO4 (phosphoric acid) as designated.
ars represent mean ± S.D. of the ABSU470 values from three different experiments
erformed in triplicate.
ith both heat and urea, their treatment order seemed to inﬂu-
nce the outcomes. The samples with heat treatment after urea
ddition showed more severe changes than the opposite order,
nd this result was observed by both native gel electrophoresis
nd CAB assay (Fig. 4C and D). The urea-treated HSA is prone to
ose helical content due to high pH which leads to the reduction
f Co-HSA binding which is consistent with the pH effect on HSA
onformation; pH affects the reversible conformational transition
f HSA. HSA, called the fast-migration form at pH 2.7–4.3, attains
n increase in viscosity, low solubility and signiﬁcant loss in heli-
al contents. HSA, termed basic form at pH greater than 8.0, also
oses -helix and has the increased afﬁnity for some ligands. HSA,
amed neutral form at pH 4.3–8.0, adopts heart-shaped structure
1,13,42,43].
.5. Comparison between the ACB test and the CAB assay
CAB assay was compared to the ACB test. The ACB test was
erformed by modifying the ﬁnal volume to 200 l, the same as
hat of the CAB assay, while maintaining the concentrations and
he ratios of each reagent. As a result, it showed such low sen-
itivity that the ABSU470 of control was below 0.2, which made
t indistinguishable with the other samples (Fig. 5, ‘control’ lane).
hen different amounts of H3PO4 were added to monitor the pH
ffects, and since the original method did not contain any buffer
olution and the ABSU470 of control was so low, it was impossible
o observe whether the decrease of pH affected the cobalt bind-
ng afﬁnity to HSA (Fig. 5, ‘added 10 mM phosphoric acid’ lane).
lso, white precipitation was observed in the ACB test-performed
amples with decreased pH while CAB assay was affordable to
valuate the pH effect without white precipitation (Supplemen-
ary Fig. S2 of Supplementary material). It suggested the buffering
apacity of CAB assay is important to evaluate pH-induced HSA
onformational change through monitoring Co-HSA binding and
iniaturized method of CAB assay is sensitive enough for the eval-
ation of HSA conformational change.
. Conclusion
The CAB assay was set up and validated in the current study
y improving the ACB test reported by Bar-Or et al. [26]. Then the
ptimized and validated assay can be applied (1) for predicting the
ormal conformation-adopted HSA concentration in a sample with
 small volume which makes it applicable in mice models (Fig. 2),
2) for detecting the decrease of Co-HSA binding leading to predic-
ion of HSA conformational changes caused by various stimulants
[ Biomedical Analysis 91 (2014) 17– 23
including pH, NO, heat and urea (Figs. 3A and 4), (3) for ultimately
detecting the differences in co-binding afﬁnity caused not only by
the N-terminal modiﬁcations as suggested by Bar-Or et al., but also
by the overall structural changes of the albumin itself, with selectiv-
ity over similar proteins such as ovalbumin (Fig. 3B) and sensitivity
(Fig. 5) without disruption of the pH-mediated Co-DTT interac-
tion (Fig. 3A). Albumin injections are widely used in patients with
liver disease, kidney disease, malnutrition, chronic disease, or even
cancer. Recent studies have also shown that albumin has neuropro-
tective effects after cerebral ischemia or brain damage relating to
these occurrences. This effect is assumed to be by the anti-oxidative
effect of albumin, but further research is still needed [44]. Despite
the valuable effects of albumin on the human body, there are some
issues left to be solved: no standard albumin is available; there is
a possibility for albumin to change its conformation depending on
the environment, which is likely to alter its biological functions;
commercially available albumin injections are validated only by
biological product criteria and tests [45], which only mention the
total content of albumin through measuring nitrogen contents but
nothing of structural changes. Conclusively, the ﬁndings in this
paper indicate that the CAB assay may  be applicable in albumin
related research, including quality control of albumin injections
with reliable efﬁciency and convenience.
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